Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.

By Renee E. Amori, Joseph Lau, AG Pittas. Journal of the American Medical Association (JAMA), 2007

1,106 citations recorded by the source corpus.

Subfields: General Health Professions, Philosophy

View Paper: https://www.semanticscholar.org/paper/d1715e8a30ec692a3eb2a2cec718805efb71d93f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Citations in the corpus

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. (2009, background): “No single agent has proven to be capable of reducing body weight more than 5–10% in the obese populatio”
The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “The most frequently reported adverse events were nausea and vomiting, especially at the higher doses, and two cases of pancreatitis have been reported (Amori et al., 2007; Vilsbøll et al., 2007; Garber et al., 2008b; Madsbad, 2008).”
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes (2008, result): “The number of reported urinary tract infections was similar among dapagliflozin, metformin, and placebo groups and is consistent with rates reported in type 2 diabetic patients (24).”
Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis (2020, neutral): “Two recent meta-analyses had shown that DPP4 inhibitors increased the risk of various infections [42,43] while a third meta-analysis showed that there is no increased risk of infections with DPP4 inhibitors [44].”
Update on the treatment of type 2 diabetes mellitus. (2016, background): “Commonly reported side effects include headache, nasopharyngitis, and upper respiratory tract infection [124,125] .”
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013, neutral): “5% YY Negligible risk as monotherapy Improved cardiovascular outcomes in overweight subjects Contraindicated if CrCl/eGFR <30 mL/min or hepatic failure Caution if CrCl/eGFR <60 mL/min Weight neutral as monotherapy, promotes less weight gain when combined with other antihyperglycemic agents, includin”